Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guru Subramanian Guru Murthy

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Haematologica|July 24, 2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Samuel J Yates, Julian J Weiss, Abigail Sneider, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2025
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic MalignanciesMichal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, et al.
Leukemia & Lymphoma|September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemiaMuhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 21, 2018
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient SettingGuru Subramanian Guru Murthy, Parameswaran N Hari, Aniko Szabo, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Leukemia|February 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Talha Badar, Ehab Atallah, Rory Shallis, et al.
Haematologica|April 4, 2024
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemiaGuru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, et al.
American Journal of Hematology|January 6, 2023
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemiaGuru Subramanian Guru Murthy, Brent R Logan, Stephanie Bo-Subait, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Haematologica|July 24, 2025
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Samuel J Yates, Julian J Weiss, Abigail Sneider, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2025
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic MalignanciesMichal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, et al.
Leukemia & Lymphoma|September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemiaMuhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 21, 2018
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient SettingGuru Subramanian Guru Murthy, Parameswaran N Hari, Aniko Szabo, et al.
Transplantation and Cellular Therapy|August 27, 2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell LymphomaPeter A Riedell, Mehdi Hamadani, Kwang W Ahn, et al.
Leukemia|February 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Talha Badar, Ehab Atallah, Rory Shallis, et al.
Haematologica|April 4, 2024
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemiaGuru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, et al.
American Journal of Hematology|January 6, 2023
Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemiaGuru Subramanian Guru Murthy, Brent R Logan, Stephanie Bo-Subait, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
Pageof 6